/PRNewswire/ Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the.
Balaxi Pharmaceuticals further diversifies geographical mix, reports 23% YoY increase in Profit After Tax for Q1FY22 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Balaxi Pharmaceuticals reports a PAT of INR 381 million for FY21; further strengthens the Product Pipeline
HYDERABAD, India, May 24, 2021 /PRNewswire/ Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the quarter and year ended 31st March 2021.
Financial Highlights - Q4 & FY21:
16.5%
The Company recorded a revenue of INR 530 million for Q4F21, the drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday.
EBITDA of INR 100 million for Q4FY21; EBITDA margin stood at 18.9%.
Reported PAT of INR 84 million for Q4FY21.
Balaxi Pharmaceuticals reports a PAT of INR 381 million for FY21; further strengthens the Product Pipeline prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.